Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biomarin Pharmaceutical's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.98.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biomarin Pharmaceutical couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for Biomarin Pharmaceutical's Cash-to-Debt or its related term are showing as below:
BMRN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.88 Med: 1.07 Max: 1.47
Current: 0.98
During the past 13 years, Biomarin Pharmaceutical's highest Cash to Debt Ratio was 1.47. The lowest was 0.88. And the median was 1.07.
Biomarin Pharmaceutical Cash-to-Debt Historical Data
The historical data trend for Biomarin Pharmaceutical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
|
Biomarin Pharmaceutical Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
0.88 |
0.98 |
0.93 |
1.18 |
0.98 |
|
Biomarin Pharmaceutical Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.18 |
1.05 |
1.07 |
1.03 |
0.98 |
Competitive Comparison
For the Biotechnology subindustry, Biomarin Pharmaceutical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's Cash-to-Debt falls into.
Biomarin Pharmaceutical Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Biomarin Pharmaceutical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Biomarin Pharmaceutical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description
Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Executives
| Jean Jacques Bienaime |
director, officer: Chief Executive Officer |
925 PAGE MILL ROAD, PALO ALTO CA 94304 |
| George Eric Davis |
officer: VP, General Counsel |
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
| Jeffrey Robert Ajer |
officer: EVP, Chief Commercial Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
| Henry J Fuchs |
officer: Chief Medical Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
| Charles Greg Guyer |
officer: EVP, Chief Technical Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901 |
| Brian Mueller |
officer: EVP, Chief Financial Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
| Mark J Alles |
director |
C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Elizabeth M Anderson |
director |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
| Maykin Ho |
director |
C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Erin Burkhart |
officer: GVP, Chief Accounting Officer |
C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901 |
| V Bryan Lawlis |
director |
|
| Richard A Meier |
director |
C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
| Dennis Slamon |
director |
770 LINDARO STREET, SAN RAFAEL CA 94901 |
| Michael G Grey |
director |
C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
| Pyott David E I |
director |
C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612 |
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your